Manchester, KR; Lomas, EC; Waters, L; Dempsey, FC; Maskell, PD. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test. Analysis, 1 Jan 2018, 10 (1), 37-53. 713 kB. https://doi.org/10.1002/dta.2211 #2C
EMCDDA. New drugs in Europe, 2012, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2013. 773 kB. #49
Bergstrand, MP; Helander, A; Hansson, T; Beck, O. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test. Analysis, 1 Apr 2017, 9 (4), 640-645. 522 kB. https://doi.org/10.1002/dta.2003
Moosmann, B; King, LA; Auwärter, V. Designer benzodiazepines: A new challenge. World Psychiatry, 0000, 14 (2), 248-248. 49 kB. https://doi.org/10.1002/wps.20236
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Moosmann, B; Auwärter, V. Designer benzodiazepines: Another class of new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 383-410. 497 kB. https://doi.org/10.1007/164_2018_154 #Pyrazolam
· Isomer Design